实体瘤治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按癌症类型、药物类型和地理划分。

市场快照

Solid Tumor Therapeutics Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

实体瘤治疗市场预计在预测期内的复合年增长率为 15%。导致该市场增长的主要因素包括卵巢癌、胰腺癌和前列腺癌的新产品批准,以及政府提高癌症意识的举措。此外,另一个重要的驱动因素是癌症发病率的增加。例如,癌症对世界各地的社会都有重大影响。2016年最常见的癌症是乳腺癌、肺癌和支气管癌、前列腺癌、结肠癌和直肠癌、膀胱癌、皮肤黑色素瘤、非霍奇金淋巴瘤、甲状腺癌、肾癌和肾盂癌、白血病、子宫内膜癌、和胰腺癌。

根据《世界癌症报告》,到 2020 年,癌症发病率可能会进一步增加 50%,达到 1500 万新病例。它还提供了明确的证据,表明政府和卫生从业者的健康生活方式和公共卫生行动可以防止这一趋势,并预防全球多达三分之一的癌症。癌症统计和数据方面的领先机构美国癌症协会报告称,2016 年美国因癌症估计有 1,685,210 例新的癌症病例和 595,690 例死亡。因此,预计在预测期内,越来越多的患者将推动市场。

然而,诸如严格的监管改革和仿制药竞争导致的价格侵蚀等因素可能会阻碍该市场的增长。

报告范围

实体瘤疗法是专门治疗各种癌症的药物,例如乳腺癌、肺癌、结直肠癌、前列腺癌、宫颈癌等。实体瘤是一种异常的组织块,通常不包含囊肿或液体区域。

By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Other Cancer Types
By Drug Type
Carboplatin
Cisplatin
Gemcitabine
Paclitaxel
Doxorubicin
Bevacizumab
Erlotinib
Sunitinib
Everolimusa
Other Drug Types
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

乳腺癌预计将占据癌症细分市场的主要收入份额

乳腺癌是主要癌症类型之一,目前正在开发新的基于免疫的癌症治疗方法。超过 80% 的癌症是由实体瘤引起的,实体瘤在特定器官、组织或腺体中以细胞团的形式生长。根据美国癌症协会的数据,截至 2018 年,预计美国约有 268,670 例新的乳腺癌病例。甚至几家大公司也在投资开发新的癌症治疗方法。例如,辉瑞公司的 Ibrance(palbociclib)用于治疗 ER 阳性、HER2 阴性乳腺癌,已于 2015 年 2 月获得批准。两种药物联合使用的试验发现,11% 的肿瘤完全清除HER2 阳性乳腺癌患者的数量减少到另外 17% 的“最小”尺寸。近 90% 的人看到癌细胞数量减少。因此,随着新药的进入,预计该细分市场将继续领先,因为病例数量也有助于增长。

Solid Tumor Therapeutics Market

北美在市场上占主导地位,预计在预测期内也会如此

北美目前在实体瘤治疗市场上占据主导地位,预计将在未来几年继续占据主导地位。在北美,美国拥有最大的市场份额。这主要归因于癌症发病率的提高和人们意识的提高,而发达的医疗保健基础设施的存在正在推动预测期内市场的增长。

Solid Tumor Therapeutics Market

竞争格局

实体瘤治疗市场竞争适度,由几个主要参与者组成。就市场份额而言,目前很少有主要参与者主导市场。随着癌症治疗需求的增加和癌症患病率的增加。然而,市场中少数较小的参与者进入除外,他们可能占有相当大的份额。该市场的一些主要参与者包括雅培公司、安进公司、阿斯利康公司、F. Hoffmann-La Roche AG 和葛兰素史克公司等。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Cancer

      2. 4.2.2 New Product Approvals in Ovarian, Pancreatic, and Prostate Cancers

      3. 4.2.3 Increasing Government Initiatives for Cancer Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Reforms

      2. 4.3.2 Price Erosion due to Generic Competition

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Breast Cancer

      2. 5.1.2 Lung Cancer

      3. 5.1.3 Colorectal Cancer

      4. 5.1.4 Prostate Cancer

      5. 5.1.5 Cervical Cancer

      6. 5.1.6 Other Cancer Types

    2. 5.2 By Drug Type

      1. 5.2.1 Carboplatin

      2. 5.2.2 Cisplatin

      3. 5.2.3 Gemcitabine

      4. 5.2.4 Paclitaxel

      5. 5.2.5 Doxorubicin

      6. 5.2.6 Bevacizumab

      7. 5.2.7 Erlotinib

      8. 5.2.8 Sunitinib

      9. 5.2.9 Everolimusa

      10. 5.2.10 Other Drug Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 AstraZeneca PLC

      4. 6.1.4 Baxter International Inc.

      5. 6.1.5 Biogen Inc.

      6. 6.1.6 Boehringer Ingelheim GmbH

      7. 6.1.7 Bristol-Myers Squibb Company

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 F. Hoffmann-La Roche AG

      10. 6.1.10 GlaxoSmithKline PLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Solid Tumor Therapeutics Market market is studied from 2018 - 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories Inc., Amgen Inc., AstraZeneca PLC, Hoffmann-La Roche AG, GlaxoSmithKline PLC are the major companies operating in Solid Tumor Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!